An Integrated Approach to CAR-T Cell Therapy in Prostate Cancer

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer

IM Everard, MJ de Veer, EM Kwan, NL Lister, S Keerthikumar, A Ryan, D Sivaratnam, MB Haskali, GP Risbridger, LH Porter, RA Taylor

2026-12-01

Background: [¹⁷⁷Lu]Lu-PSMA radioligand therapy targets metastatic castration-resistant prostate cancer by delivering ra..

Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8 T cells in lymph nodes

J Lai, CW Chan, JD Armitage, KM Audsley, YK Huang, EB Derrick, LS Carstensen, CM Scheffler, ME Jones, K Sek, N Principe, JS Kim, IG House, AXY Chen, KM Yap, J Middelburg, I Munoz, D Nguyen, J Tong, TX Hoang

2026-03-01

Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation ..

Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery

AXY Chen, KM Yap, JS Kim, K Sek, YK Huang, PA Dunbar, V Wiebking, JD Armitage, I Munoz, KL Todd, EB Derrick, D Nguyen, J Tong, CW Chan, TX Hoang, KM Audsley, MJ van Elsas, J Middelburg, JN Lee, MN de Menezes

2025-08-07

The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen hetero..

p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer

HW Gomes, NL Lister, S Keerthikumar, B Niranjan, MG Richards, A Ryan, EM Kwan, GP Risbridger, RA Taylor

2025-07-01

Purpose: AKT inhibitors, such as capivasertib, have shown activity in specific patients with metastatic castration-resistant prost..

Immunotherapy in metastatic prostate cancer

L Dwyer, C Leslie, R Mellor, T Scheinberg, RA Taylor, LG Horvath

2025-01-01

Over the last 15 years, immunotherapy has revolutionised treatment paradigms and improved outcomes in a range of malignancies. Des..

Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies

LH Porter, SG Harrison, GP Risbridger, Natalie Lister, RA Taylor

2024-10-01

Prostate cancer is primarily hormone-dependent, and medical treatments have focused on inhibiting androgen biosynthesis or signali..